Medical management of neurocysticercosis

Neurology India

Volumn 49, Issue 4, 2001, Pages 329-337

  Garg, R K ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Anticysticercal therapy; Management; Neurocysticercosis

Indexed keywords

ALBENDAZOLE; ANTICONVULSIVE AGENT; ANTIPARASITIC AGENT; CORTICOSTEROID DERIVATIVE; DEXAMETHASONE; DRINKING WATER; PLACEBO; PRAZIQUANTEL; PREDNISOLONE; PREDNISONE;

BRAIN CYSTICERCOSIS; BRAIN EDEMA; BRAIN INFARCTION; BRAIN INJURY; CALCIFICATION; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL TRIAL; DEATH; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; ENCEPHALITIS; ENDOSCOPIC SURGERY; EVIDENCE BASED MEDICINE; FOOD DRUG INTERACTION; HEMATOLOGIC DISEASE; HUMAN; LIVER DISEASE; LONG TERM CARE; META ANALYSIS; MORTALITY; NEUROCYSTICERCOSIS; NEUROLOGIC DISEASE; PARASITE PREVALENCE; PREVENTIVE MEDICINE; REVIEW; RISK MANAGEMENT; SEIZURE; SHORT COURSE THERAPY; SPINAL CORD INFECTION; STROKE; TREATMENT FAILURE; TREATMENT OUTCOME; VASCULITIS; WASTE DISPOSAL; WATER QUALITY;

ADRENAL CORTEX HORMONES; ANTHELMINTICS; HUMANS; NEUROCYSTICERCOSIS;

EID: 0035705088     PISSN: 00283886     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Drugs five years later: Praziquantel
2. Human cysticercosis: Parasitology, pathology clinical manifestation and available treatment
3. Mode of action of anticestodal agents
4. Pharmacokinetic optimization of the treatment of neurocysticercosis
5. Neurocysticercosis: Optimal dose treatment with albendazole
6. Albendazole therapy for neurocysticercosis: A prospective double-blind trial comparing 7 versus 14 days of treatment: Cysticercosis working group in Peru
7. Presentacion de un caso clinico de cisticercosis cerebral curado medicamente con un nuevo formaco: Praziquantel
8. Therapy of parenchymal brain cysticercosis with praziquantel
9. Long-term results of praziquantel therapy in neurocysticercosis
10. Selective indications for the use of praziquantel in the treatment of brain cysticercosis
11. Single-day praziquantel therapy for neurocysticercosis
12. Single-day praziquantel versus 1-week albendazole for neurocysticercosis
13. Albendazole therapy for neurocysticercosis
14. Selective sensitivity of cysts to praziquantel and albendazole in a case of cerebral cysticercosis
15. Therapy for neurocysticercosis: Comparison between albendazole and praziquantel
16. Combination of therapeutic regimes of anticysticercal drug for parenchymal brain cysticercosis
17. Neurocysticercosis: An update
18. Cysticercosis and epilepsy: A critical review
19. Disseminated cysticercosis: New observations including CT scan findings and experience with treatment by praziquantel
20. Should the patients with numerous cysticerci be treated with corticosteroids only?
21. Heavy nonencephalitic cerebral cysticercosis in tapeworm carriers. The cysticercosis working group in Peru
22. Severe forms of neurocysticercosis: Treatment with albendazole
23. The use of albendazole in patients with single lesions enhanced on contrast CT
24. Albendazole in single CT lesions in epilepsy
25. Albendazole therapy in children with focal seizures and single small enhancing computerized tomographic lesions: A randomized, placebo-controlled, double-blind trial
26. Albendazole therapy for subarachnoid and ventricular cysticercosis: Case report
27. Albendazole therapy for giant subarachnoid cysticerci
28. Medical and surgical treatment in neurocysticercosis, as a magnetic resonance study of 161 cases
29. Albendazole therapy for subarachnoid cysticercosis: Clinical and neuroimaging analysis of 17 patients
30. Albendazole and praziquantel treatment in neurocysticercosis of the fourth ventricle
31. Intramedullary cysticercosis cured with drug treatment: A case report
32. Intramedullary spinal cysticercosis: Response to albendazole: Case reports and review of literature
33. Intraparenchymal cerebral cysticercosis in children: Diagnosis and treatment
34. Cerebral cysticercosis: Documentation of natural history with CT
35. Is the course of neurocysticercosis modified by treatment with antihelminthic agents?
36. Vanishing CT lesions in epilepsy
37. Medical treatment of cysticercosis: Ineffective
38. Is medical treatment of neurocysticercosis effective?
39. Relationship between epilepsy and tropical diseases
40. Neuroimaging abnormalities in Indian patients with uncontrolled partial seizures
41. Epilepsy due to neurocysticercosis: Analysis of 203 patients
42. The course of seizures after treatment for cerebral cysticercosis
43. Prognostic factors for seizure recurrence after withdrawal of antiepileptic drugs in patients with neurocysticercosis
44. Prognosis of epilepsy associated with single CT enhancing lesion: A long term follow-up study
45. Neurocysticercosis
46. Controversies in the management of cysticercosis
47. Treating neurocysticercosis medically: A systemic review of randomized controlled trials
48. Albendazole in neurocysticercosis
49. Drug treatment of neurocysticercosis
50. Lacunar syndrome due to neurocysticercosis
51. Large cerebral infarction during praziquantel therapy in neurocysticercosis
52. Neurological symptoms in occult neurocysticercosis after single taenicidal dose of praziquantel
53. Adverse reactions during treatment of neurocysticercosis with praziquantel
54. A resistant case of neurocysticercosis
55. Failure of albendazole therapy in two common types of parenchymal neurocysticercosis
56. Effects of predinisone on ventriculoperitoneal shunt infection in hydrocephalus secondary to cysticercosis: A preliminary study